Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.50 |
| ▸ | NCF1 | P14598 | 2/20 | 0.48 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | ACHE | P22303 | 2/20 | 0.43 |
| ▸ | GLA | P06280 | 2/20 | 0.43 |
| ▸ | CASP1 | P29466 | 2/20 | 0.43 |
| ▸ | CASP7 | P55210 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | NQO2 | P16083 | 1/20 | 0.43 |
| ▸ | DRD1 | P21728 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30800556 | 0.98 | GPR3 (0.48) | GPR3NCF1DCPSKDM4EALDH1A1 | |
| Ammonia Solution, Strong SCHEMBL27701708 | 0.98 | GPR3 (0.48) | GPR3NCF1DCPSKDM4EALDH1A1 | |
| Formic Acid SCHEMBL30452445 | 0.89 | LCK (0.41) | GPR3NCF1DCPSKDM4EALDH1A1 | |
| SCHEMBL27722231 | 0.86 | HDAC3 (0.41) | GPR3NCF1DCPSKDM4EALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL29015612 | 0.83 | LCK (0.44) | GPR3NCF1DCPSKDM4EALDH1A1 | |
| SCHEMBL30800543 | 0.74 | MEN1 (0.40) | KDM4EALDH1A1HSD17B10SMN1; SMN2ACHE | |
| SCHEMBL11732569 | 0.74 | LOXL2 (0.52) | GPR3KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL276531 | 0.73 | GPR3 (0.50) | GPR3KDM4EALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL436407 | 0.73 | GPR3 (0.50) | GPR3KDM4EALDH1A1SMN1; SMN2TDP1 | |
| SCHEMBL276532 | 0.73 | GPR3 (0.50) | GPR3KDM4EALDH1A1SMN1; SMN2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 209 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251617-B1 | (AZA)QUINOLINE 4-AMINES DERIVATIVES AS P2X3 INHIBITORS | CHIESI FARM SPA (IT) | 2025-03-12 | — | — | EP | claimed |
| CN-100473384-C | Pharmaceutical formulations comprising an immune response modifier | 3M INNOVATIVE PROPERTIES CO (US) | 2009-04-01 | — | — | CN | claimed |
| CN-101163475-A | Aqueous gel formulations containing 1- (2-methylpropyl) -1H-imidazo [4, 5-C ] [1,5] naphthyridin-4-amine | TAKEDA PHARMACEUTICAL (JP) | 2008-04-16 | — | — | CN | claimed |
| CN-1610550-A | Pharmaceutical formulations comprising an immune response modifier | 3M INNOVATIVE PROPERTIES CO (US) | 2005-04-27 | — | — | CN | claimed |
| CN-1523987-A | Immune response modifiers for the treatment of periodontal disease | 3M创新有限公司 | 2004-08-25 | — | — | CN | claimed |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | ANNEXON, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2025-09-09 | — | — | US | disclosed |
| EP-4565574-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2025-06-11 | — | — | EP | disclosed |
| CN-119731159-A | SARS-CoV2 main proteinase inhibitor | 吉利德科学公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | GILEAD SCIENCES, INC. | 2025-02-06 | — | — | US | disclosed |
| CN-118715231-A | Complement factor inhibitors and uses thereof | 安尼艾克松股份有限公司 | 2024-09-27 | — | — | CN | disclosed |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | GILEAD SCIENCES, INC. (US) | 2024-09-17 | — | — | US | disclosed |
| US-4886800-A | Substituted cinnoline derivatives as CNS depressants | ICI AMERICAS INC. (US) | 1989-12-12 | — | — | US | disclosed |
| EP-0328282-A2 | Pharmaceutical | ICI AMERICAS INC. (US) | 1989-08-16 | — | — | EP | disclosed |
| EP-0172427-B1 | PROCESS FOR PRODUCTION OF VINYL CHLORIDE POLYMER | Shin-Etsu Chemical Co., Ltd. (JP) | 1989-07-05 | — | — | EP | disclosed |
| US-4758639-A | Process for production of vinyl polymer | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-19 | — | — | US | disclosed |
| US-4757124-A | Suspension or emulsion polymerizing vinyl chloride monomer or mixture of vinyl chloride with vinyl monomer copolymerizable therewith in reactor with walls coated with antiscaling compound containing dye or pigments | SHIN-ETSU CHEMICAL CO., LTD. (JP) | 1988-07-12 | — | — | US | disclosed |
| CN-86104358-A | The preparation method of cinnoline compound | — | 1987-04-01 | — | — | CN | disclosed |
| EP-0205272-A2 | Cinnoline derivatives | ICI AMERICAS INC. (US) | 1986-12-17 | — | — | EP | disclosed |
| EP-0172427-A2 | Process for production of vinyl chloride polymer | Shin-Etsu Chemical Co., Ltd. (JP) | 1986-02-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042915-A1 | SARS-COV2 MAIN PROTEASE INHIBITORS | ACE2, TMPRSS2, ACE | GPR3 3606/4885NCF1 3538/4885DCPS 708/4885 |
| US-12091420-B2 | SARS-COV2 main protease inhibitors | ACE2, TMPRSS2, ACE | GPR3 3606/4885NCF1 3538/4885DCPS 708/4885 |
| US-12410183-B2 | Sars-cov2 main protease inhibitors | ACE2, TMPRSS2, ACE | GPR3 3606/4885NCF1 3538/4885DCPS 708/4885 |
| US-12509474-B2 | Inhibitors of complement factors and uses thereof | SSB, UACA, CFH | GPR3 3276/4885NCF1 487/4885DCPS 2467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.